康恩贝TFA003片临床试验获批

Core Viewpoint - Kang En Bei (600572) has received approval from the National Medical Products Administration for clinical trials of TFA003, a drug aimed at treating diabetic kidney disease [1] Group 1: Company Developments - Kang En Bei's wholly-owned subsidiary, Hangzhou Kang En Bei Pharmaceutical Co., Ltd., has been granted a Clinical Trial Approval Notice for TFA003 [1] - The drug has shown significant efficacy in improving renal function indicators in both urine and blood, as well as enhancing glomerular filtration and tubular reabsorption functions in animal studies [1] Group 2: Drug Potential - TFA003 demonstrates potential as a new drug for diabetic kidney disease, based on its pharmacological and pharmacokinetic results from preclinical studies [1] - The drug's ability to improve renal pathological morphology further supports its development as a treatment option for diabetic nephropathy [1]